Xilio Therapeutics Unleashes Potential of Immuno-Oncology Therapies with New Collaboration.

Xilio Therapeutics, a biotechnology company, is focusing on unleashing the potential of immuno-oncology therapies. The company is developing programs with AbbVie and Gilead, aiming to receive contingent payments under their collaboration agreements. Xilio is working to advance its product candidates in various indications, with a goal of achieving milestones and expanding its pipeline. The company expects its cash to fund operations and development plans, with potential for additional capital to support future growth.

Waltham, MA - Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company, has announced updated data from its ongoing Phase 2 clinical trial evaluating vilastobart, a tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4, in combination with atezolizumab (Tecentriq) in patients with metastatic MSS CRC [1]. The data will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

The preliminary objective response rate (ORR) for patients with metastatic MSS CRC without liver metastases was 26%, with seven partial responses (PRs) and six confirmed PRs. Responses were deep and durable, with reductions in target lesions of up to 71% from baseline and responders ongoing on treatment for up to 37 weeks. The combination therapy demonstrated a differentiated and well-tolerated safety profile, with a low incidence of immune-mediated adverse events (imAEs) [1].

Katarina Luptakova, M.D., chief medical officer of Xilio, stated, "These Phase 2 data for the combination of vilastobart and atezolizumab demonstrate a meaningfully differentiated safety and tolerability profile for an anti-CTLA-4 combination therapy, together with a preliminary 26% objective response rate in patients with late-line metastatic MSS CRC without liver metastases." Marwan G. Fakih, M.D., professor in the Department of Medical Oncology and Therapeutics Research at City of Hope, expressed enthusiasm for the potential of vilastobart as a combination therapy across a range of tumor types [1].

Xilio is currently evaluating the safety of the combination in Phase 1C dose escalation in patients with advanced solid tumors and the efficacy and safety of the combination in Phase 2 in patients with metastatic microsatellite stable colorectal cancer (MSS CRC) with and without liver metastases. The company is seeking opportunities to partner the vilastobart program to accelerate and expand further development.

References:
[1] https://www.marketscreener.com/quote/stock/XILIO-THERAPEUTICS-INC-128506326/news/Xilio-Therapeutics-Announces-Updated-Phase-2-Data-for-Vilastobart-a-Tumor-Activated-Anti-CTLA-4-in-50128672/